These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20411786)

  • 1. Neurogenesis in substantia nigra of parkinsonian brains?
    Arias-Carrión O; Yamada E; Freundlieb N; Djufri M; Maurer L; Hermanns G; Ipach B; Chiu WH; Steiner C; Oertel WH; Höglinger GU
    J Neural Transm Suppl; 2009; (73):279-85. PubMed ID: 20411786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult neurogenesis and Parkinson's disease.
    Arias-Carrión O; Freundlieb N; Oertel WH; Höglinger GU
    CNS Neurol Disord Drug Targets; 2007 Oct; 6(5):326-35. PubMed ID: 18045161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing neurogenesis for the possible treatment of Parkinson's disease.
    Lamm O; Ganz J; Melamed E; Offen D
    J Comp Neurol; 2014 Aug; 522(12):2817-30. PubMed ID: 24723264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
    Damier P; Hirsch EC; Agid Y; Graybiel AM
    Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for neurogenesis in the adult mammalian substantia nigra.
    Zhao M; Momma S; Delfani K; Carlen M; Cassidy RM; Johansson CB; Brismar H; Shupliakov O; Frisen J; Janson AM
    Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7925-30. PubMed ID: 12792021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Morphometric assessment of lesions in the dopaminergic nigrostriatal system in Parkinson disease].
    Bertrand E; Lechowicz W; Szpak GM; Dymecki J
    Neurol Neurochir Pol; 1996; 30(5):751-62. PubMed ID: 9148173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease.
    Kim M; Cho KH; Shin MS; Lee JM; Cho HS; Kim CJ; Shin DH; Yang HJ
    Int J Mol Med; 2014 Apr; 33(4):870-8. PubMed ID: 24535622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-hydroxydopamine-induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis.
    Fricke IB; Viel T; Worlitzer MM; Collmann FM; Vrachimis A; Faust A; Wachsmuth L; Faber C; Dollé F; Kuhlmann MT; Schäfers K; Hermann S; Schwamborn JC; Jacobs AH
    Eur J Neurosci; 2016 May; 43(10):1352-65. PubMed ID: 26950181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of substantia nigra neurogenesis in homeostasis and dopaminergic degeneration: beneficial effects of the microneurotrophin BNN-20.
    Mourtzi T; Dimitrakopoulos D; Kakogiannis D; Salodimitris C; Botsakis K; Meri DK; Anesti M; Dimopoulou A; Charalampopoulos I; Gravanis A; Matsokis N; Angelatou F; Kazanis I
    Stem Cell Res Ther; 2021 Jun; 12(1):335. PubMed ID: 34112234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.
    Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP
    Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
    Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
    Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
    Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantia nigra and Parkinson's disease: a brief history of their long and intimate relationship.
    Parent M; Parent A
    Can J Neurol Sci; 2010 May; 37(3):313-9. PubMed ID: 20481265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newborn dopaminergic neurons are associated with the migration and differentiation of SVZ-derived neural progenitors in a 6-hydroxydopamin-injected mouse model.
    Xie MQ; Chen ZC; Zhang P; Huang HJ; Wang TT; Ding YQ; Qi SS; Zhang C; Chen SX; Zhou P; Shao CC; Liao M; Sun CY
    Neuroscience; 2017 Jun; 352():64-78. PubMed ID: 28385636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracerebroventricularly-administered 1-methyl-4-phenylpyridinium ion and brain-derived neurotrophic factor affect catecholaminergic nerve terminals and neurogenesis in the hippocampus, striatum and substantia nigra.
    Chen JF; Wang M; Zhuang YH; Behnisch T
    Neural Regen Res; 2018 Apr; 13(4):717-726. PubMed ID: 29722326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis.
    Farzanehfar P
    Neurochem Res; 2016 Dec; 41(12):3161-3170. PubMed ID: 27613619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
    Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
    J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
    Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
    J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.